Prelude Therapeutics Incorporated
PRLD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.19 | 1.04 | -0.07 |
| FCF Yield | -107.66% | -42.90% | -30.32% | -14.49% |
| EV / EBITDA | -0.54 | -1.36 | -1.46 | -3.54 |
| Quality | ||||
| ROIC | -89.98% | -51.41% | -56.74% | -38.98% |
| Gross Margin | 100.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.88 | 0.73 | 0.75 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 6.26% | -27.47% | -1.04% | -83.46% |
| Safety | ||||
| Net Debt / EBITDA | -0.04 | 0.06 | 0.24 | 0.27 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,592.65 | -1,430.03 | -813.15 | -1,275.79 |